

LISTING OF CLAIMS

Claims 1-8 (canceled).

Claim 9 (currently amended): A method for the treatment of diabetic ischemic disease in a subject, comprising administering a therapeutically effective amount of a nucleic acid encoding hepatocyte growth factor to the muscle of an ischemic site, thereby treating the diabetic ischemic disease, wherein the nucleic acid encoding the hepatocyte growth factor is administered to the subject once every few weeks.

Claim 10 (canceled).

Claim 11 (previously presented): The method according to claim 9, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic myocardial infarction.

Claim 12 (original): The method according to claim 11, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

Claim 13 (canceled).

Claim 14 (previously presented): The method according to claim 9, wherein the nucleic acid encoding the hepatocyte growth factor is in the form of a Sendai virus (HVJ)-liposome.

Claim 15 (canceled).

Claim 16 (previously presented): The method according to claim 9, wherein at least 50 μ g of the nucleic acid encoding the hepatocyte growth factor is administered to the subject.

Claims 17-22 (canceled).

Claim 23 (currently amended): A method for the treatment of diabetic ischemic disease in a subject, comprising administering a therapeutically effective amount of a nucleic acid encoding hepatocyte growth factor to the muscle of an ischemic site, thereby treating the diabetic ischemic disease, wherein the nucleic acid encoding the hepatocyte growth factor is administered to the subject once every few days.

Claim 24 (previously presented): The method according to claim 23, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic myocardial infarction.

Claim 25 (previously presented): The method according to claim 24, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

Claim 26 (previously presented): The method according to claim 24, wherein the nucleic acid encoding the hepatocyte growth factor is in the form of a Sendai virus (HVJ)-liposome.

Claim 27 (previously presented): The method according to claim 23, wherein at least 50 μg of the nucleic acid encoding the HGF is administered to the subject.

Claims 28-43 (canceled).

Claim 44 (new): A method for the treatment of diabetic ischemic disease in a subject, comprising administering a therapeutically effective amount of a nucleic acid encoding hepatocyte growth factor to the muscle of an ischemic site, wherein at least 50 μg of the nucleic acid encoding the hepatocyte growth factor is administered to the subject, thereby treating the diabetic ischemic disease.

Claim 45 (new): The method according to claim 44, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic myocardial infarction.

Claim 46 (new): The method according to claim 45, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

Claim 47 (new): The method according to claim 45, wherein the nucleic acid encoding the hepatocyte growth factor is in the form of a Sendai virus (HVJ)-liposome.